Atea Pharmaceuticals (NASDAQ: AVIR) net income
Atea Pharmaceuticals reported a net loss of $158.3m for fiscal 2025; in fiscal 2024 it reported a net loss of $168.4m. Earnings per share were −$1.94.
Atea Pharmaceuticals's best year of the last 7 was fiscal 2021. It reported a loss in 6 of those 7 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$158.3m | — | — | −$1.94 |
| 2024 | −$168.4m | — | — | −$2.00 |
| 2023 | −$136.0m | — | — | −$1.63 |
| 2022 | −$115.9m | −195.6% | — | −$1.39 |
| 2021 | $121.2m | — | 34.5% | $1.46 |
| 2020 | −$10.9m | — | −22.5% | −$0.51 |
| 2019 | −$14.0m | — | — | −$1.39 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Atea Pharmaceuticals net income compared with its sector
By net income for its latest fiscal year, Atea Pharmaceuticals ranks 386th of the 501 US health care companies with a page on Celsmar.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 384th | Mineralys Therapeutics | −$154.7m | — |
| 385th | Spyre Therapeutics | −$155.2m | — |
| 386th | Atea Pharmaceuticals | −$158.3m | — |
| 387th | Editas Medicine | −$160.1m | −395.0% |
| 388th | CG Oncology | −$161.0m | −3,985.0% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Atea Pharmaceuticals
- How much did Atea Pharmaceuticals earn in fiscal 2025?
- Atea Pharmaceuticals reported a net loss of $158.3m for fiscal 2025. In fiscal 2024 it reported a net loss of $168.4m.
- What are the earnings per share of Atea Pharmaceuticals?
- They were −$1.94 in fiscal 2025, compared with −$2.00 in fiscal 2024.
- What was the most profitable year for Atea Pharmaceuticals?
- Of its last 7 fiscal years, fiscal 2021, with $121.2m.
- Where does Atea Pharmaceuticals rank in its sector by net income?
- It ranks 386th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Atea Pharmaceuticals come from?
- From the annual report (Form 10-K) that Atea Pharmaceuticals files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Atea Pharmaceuticals files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019. More on Atea Pharmaceuticals: the Atea Pharmaceuticals page · annual accounts · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.